Effects of droperidol on left ventricular performance in humans
Related Experiment Video
Updated: Aug 19, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
Insights
Droperidol reduces mean arterial pressure and cardiac index in patients with coronary artery disease, primarily by decreasing left ventricular end-diastolic pressure, not affecting cardiac contractility or systemic vascular resistance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Droperidol is an antipsychotic medication with known cardiovascular effects.
- Its impact on left ventricular (LV) performance in patients with coronary artery disease (CAD) requires detailed examination.
Purpose of the Study:
- To investigate the acute effects of intravenous droperidol on left ventricular performance in patients with stable coronary artery disease.
Main Methods:
- Nine unpremedicated patients with stable CAD received 0.15 mg/kg of droperidol intravenously.
- Cardiac output (CO) and LV pressure derivatives were measured before and at various intervals up to 20 minutes post-administration.
Main Results:
- Droperidol caused a time-dependent decrease in mean arterial pressure (MAP) and cardiac index (CI).
- A transient increase in heart rate (HR) and LV pressure rise rate was observed.
- Left ventricular end-diastolic pressure (LVEDP) significantly decreased, while systemic vascular resistance (SVR) remained unchanged.
Conclusions:
- The observed fall in MAP after droperidol is mainly due to decreased CO, secondary to reduced LVEDP.
- Droperidol does not appear to negatively impact cardiac contractility or SVR in this patient population.
Abstract:
The action of droperidol on left ventricular (LV) performance was examined before angiography in nine unpremedicated patients undergoing cardiac catheterization for stable uncomplicated coronary artery disease. Using local anesthesia, catheters were placed in the left ventricle, thoracic aorta, and pulmonary artery. Cardiac output (CO) and LV pressure derivatives were measured before and 2, 5, 10, 15, and 20 min after intravenous administration of 0.15 mg/kg droperidol. Droperidol administration induced a time-dependent decrease of mean arterial pressure (MAP) (significant at 2, 10, 15, and 20 min) and of cardiac index (CI) (significant at 15 and 20 min) with maximal changes observed at 20 min (-14 per cent for MAP and -15 per cent for CI). in addition, the following changes occurred in variables related to LV performance: 1) a transient increase in both heart rate (HR) (2, 5, and 10 min) and maximum rate of rise of left ventricular pressure/instantaneous left ventricular pressure (dP . dt-1 max . IP-1) (+ 15 per cent for HR and + 14 per cent for dP .dt-1 max . IP-1); 2) an early (2 min) and sustained (5, 10, 15, and 20 min) decrease of left ventricular end-diastolic pressure (LVEDP), maximum at 5 min (-30 per cent); 3) no change in systemic vascular resistance (SVR). This study shows that the fall in MAP which occurs after intravenous administration of clinical doses of droperidol is primarily due to decreased CO, secondary to decreased LVEDP and not to changes in cardiac contractility and in SVR.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers
Cardiomyopathy II: Dilated Cardiomyopathy

